Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan, US Agree to Work Together to Develop COVID-19 Treatments: Abe
March 16, 2020
- Japan Enacts State of Emergency Bill over Coronavirus
March 13, 2020
- Japan’s Stance to Look at Overseas Examples for Copay Raises Called into Question
March 13, 2020
- PMDA Prepares “Special Leave” System for Coronavirus Infected Staffers
March 13, 2020
- Annual Drug Price Revisions “Practically Feasible”: Health Policy Advisor
March 12, 2020
- Japan Cabinet OKs Bill to Allow Govt to Declare Emergency over Coronavirus
March 11, 2020
- Japan Govt Orders 20,000 Alvesco Inhalers as Coronavirus Measure
March 11, 2020
- Japan Sets 1st Rollout of Amended PMD Law for Sept. 1
March 9, 2020
- PMDA Reviewing Safety Risks for Xofluza, Keytruda
March 9, 2020
- Japan Starts Health Coverage for COVID-19 Testing
March 6, 2020
- 7 Generic API Specifications Subject to New Rule to Address Unreasonable Price Rises
March 6, 2020
- 3 Drugs Earn Post-Launch “True Clinical Utility” Premium; Forxiga Price Flat, Rises for Canaglu and Praluent
March 5, 2020
- Price Maintenance Premium Granted to 335 APIs/555 Products; Novartis Top PMP Earner
March 5, 2020
- With 80%-Plus Gx Rates, Many One-Time Blockbusters Might Be In for Earlier “G1” Price Cuts
March 5, 2020
- Xolair Faces 37.3% Price Slash, Keytruda 20.9% in April: MHLW
March 5, 2020
- MHLW Orders Package Insert Revisions to Eliminate Vaccination Interval Restriction
March 5, 2020
- Sandostatin Now Eligible for Health Coverage for Congenital Hyperinsulinemia
March 4, 2020
- Japan Mulling Legal Preparations to Declare State of Emergency over Coronavirus
March 4, 2020
- Japan Panel Says No to Nonprescription Switch for Domperidone, Menatetrenone; Decision Now Up for Public Comments
March 3, 2020
- MHLW to Announce New NHI Prices on March 5
March 3, 2020
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…